title: Safety of type 2 diabetes treatment with repaglinide compared with glibenclamide in elderly people: A randomized, open-label, two-period, cross-over trial.
authors.affiliation: Division of Internal Medicine, University of Catania, Italy.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Papa
authors.forename: Viviana
authors.initials: V
authors.lastname: Fedele
authors.forename: Maria Rosaria
authors.initials: MR
authors.lastname: Rizzo
authors.forename: Marisa
authors.initials: M
authors.lastname: Fioravanti
authors.forename: Carmelo
authors.initials: C
authors.lastname: Leotta
authors.forename: Sebastiano Bruno
authors.initials: SB
authors.lastname: Solerte
authors.forename: Francesco
authors.initials: F
authors.lastname: Purrello
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Paolisso
mesh_terms: D000368:Aged; D002219:Carbamates / Q000009:adverse effects / Q000627:therapeutic use*; D018592:Cross-Over Studies; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005905:Glyburide / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D002219:Carbamates; D010880:Piperidines; C072379:repaglinide; D005905:Glyburide